Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026LeukemiaOpen Access

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study

View Full Paper
Ask AI
Bookmark
Share

Authors

SRSébastien RinaldettiMCMaryna ChepelevaAHA. Hedblom

Discussion

Loading...

Member takes

Overview

Randomized trial investigates molecular mechanisms of treatment-free remission in chronic myeloid leukemia, suggesting new therapeutic approaches.

Key Points

  • This research aims to understand the molecular mechanisms behind sustained treatment-free remission and relapse in chronic myeloid leukemia patients.
  • Conducted whole transcriptome gene expression analyses with NanoString nCounter in 240 CML patients and 10 healthy controls.
  • Incorporated transcriptomic data from an external dataset of 96 TKI-naïve CML patients.
  • Analyzed gene expression at the final day of TKI intake for training and validation samples.
  • TFR patients exhibited activation of GATA1, KLF1, and MYBL1 regulons associated with erythroid progenitor cells.
  • Communication between innate and adaptive immunity was maintained in TFR patients, unlike those who lost TFR.
  • Identified an FLT3 threshold that significantly differentiated two groups regarding TFR loss risk.

Cite This Study

Rinaldetti et al. (2026) studied this question.

synapsesocial.com/papers/6a362ee4db0793dc1a536818https://doi.org/10.1038/s41375-026-03001-5
View Full Paper
Ask AI
Bookmark
Share